# Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

> **NCT03070002** · PHASE2 · TERMINATED · sponsor: **Northwestern University** · enrollment: 1 (actual)

## Conditions studied

- Breast Carcinoma Metastatic in the Bone
- Circulating Tumor Cell Count
- Estrogen Receptor Positive
- HER2/Neu Negative
- Progesterone Receptor Positive
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** Denosumab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03070002
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-19
- **Primary completion:** 2018-03-06
- **Final completion:** 2018-04-24
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2018-11-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03070002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03070002, "Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03070002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*